ArticleRespirology case reports2025
Reversible ST-T Segment Changes Induced by Anamorelin: A Case Report.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reversible ST-T Segment Changes Induced by Anamorelin: A Case Report.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anamorelin has been approved for cancer cachexia in Japan. Anamorelin has been known to cause adverse events including QT prolongation and can lead to fatal arrhythmia. We report a first case of a male patient with non-small cell lung cancer who showed ST-T segment change following anamorelin. Five days after starting anamorelin, ST-segment elevation in lateral leads and reciprocal ST depression in the inferior leads were noted. He did not complain about chest pain. Neither echocardiography nor computed tomography angiography revealed abnormal findings. Anamorelin was immediately discontinued. ST-T segment change recovered gradually and returned to normal on Day 19. During the course, cardiac enzymes had never been elevated. The manufacturer reports that anamorelin is shown to weakly but competitively bind to calcium channel L-type receptors, which could inhibit repolarization. Even if patients do not complain of chest discomfort, an early ECG should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.